CD9

Across TCGA pan-cancer cohorts, CD9 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CD9 data layer compared with 26 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher CD9 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CD9 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, KICH, and LUAD are the cancer types where CD9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	DFS	Median	All	0.549	0.904	<.001	24	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
LUAD	OS	Median	All	0.313	0.812	.015	9	view →
LIHC	OS	Median	All	0.258	0.773	.018	6	view →
UCEC	DFS	Median	II,III,IV	1.000	0.445	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CD9–BRCA (DFS)

Open the BRCA breakdown →